Daniel Peterson

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Jump to: navigation, search
Daniel Peterson.png

Daniel L. Peterson, MD, is a physician in Incline Village, Nevada specializing in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). He was at the epicenter of the 1984 Incline Village chronic fatigue syndrome outbreak[1] and continues to be a leader in treatment and research about ME/CFS, serving on Simmaron Research’s Scientific Advisory Board and the Faculty of Health Sciences and Medicine at Griffith University in Queensland, Australia.[2]

He helped establish the Whittemore Peterson Institute (WPI) which was renamed in 2016 the Nevada Center for Biomedical Research.[3] He left in 2010 to return to private practice at Sierra Internal Medicine, Incline Village, Nevada.[4] In 2019, he joined the scientific advisory board of the Open Medicine Foundation.[5]

Dr. Peterson was the first physician to use Ampligen, an immunomodulator made by AIM ImmunoTech (formerly Hemispherx Biopharma), in the treatment for ME/CFS, using it on Nancy Kaiser, a very severe patient.[6] He has participated in every Ampligen trial since, up to the AMP-511, open label, cost-recovery trial available today.[7]

Several documentaries about myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) have featured Dr. Peterson, including, I Remember Me and Forgotten Plague, and the news feature, Sick and Tired.

Awards[edit | edit source]

  • 2003, Rudy Perpich Senior Lectureship Award, presented to a distinguished CFS/FM scientist, physician or healthcare worker awarded by IACFS/ME[8]
  • 2007, Nelson Gantz Outstanding Clinician Award awarded to a physician who emulates Nelson Gantz's clinical acumen, his passion for medicine, and his empathy for persons with CFS/FM awarded by IACFS/ME[8]

Writing committees[edit | edit source]

  • 2015, IOM Committee on Diagnostic Criteria for ME/CFS - Dr Peterson was a reviewer for the 2015 report produced by the Institute of Medicine's Committee on Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.[10]

Notable studies[edit | edit source]

Talks and interviews[edit | edit source]

ME/CFS Alert[edit | edit source]

Invest in ME International ME Conference[edit | edit source]

Other[edit | edit source]

Online presence[edit | edit source]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. "Dr. Dan Peterson (Sierra Internal Medicine, Incline Village, Nevada) - Health Rising". Health Rising. Retrieved August 13, 2018.
  2. "Collaborators - Simmaron Research". Simmaron Research. Retrieved August 13, 2018.
  3. "About Us". Nevada Center for Biomedical Research. Retrieved April 13, 2022.
  4. "History of Changes for Study: NCT00215813 | Study of Ampligen in Chronic Fatigue Syndrome". ClinicalTrials.gov. April 8, 2010. Retrieved April 13, 2020.
  5. "Daniel L. Peterson, MD". Open Medicine Foundation. Retrieved April 1, 2019.
  6. "TREATING THE DISEASE, NOT THE SYMPTOMS: NCF'S RESEARCH MOVES CFIDS/ME ONE STEP CLOSER TO NEOPLASTIC DISEASE PROCESS". ncf-net.org. Retrieved August 13, 2018.
  7. "Ampligen in Chronic Fatigue Syndrome". ClinicalTrials.gov. Retrieved August 13, 2018.
  8. 8.08.1 "IACFS/ME Awardees". IACFS/ME. Retrieved April 23, 2020.
  9. Carruthers, Bruce M.; Jain, Anil Kumar; De Meirleir, Kenny L.; Peterson, Daniel L.; Klimas, Nancy G.; Lerner, A. Martin; Bested, Alison C.; Flor-Henry, Pierre; Joshi, Pradip; Powles, AC Peter; Sherkey, Jeffrey; van de Sande, Marjorie (January 2003). "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome". Journal of Chronic Fatigue Syndrome. 11 (1): 7–115. doi:10.1300/j092v11n01_02. ISSN 1057-3321.
  10. Institute of Medicine (2015). Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. Washington, DC: The National Academies Press. doi:10.17226/19012. ISBN 0309316898. PMID 25695122.
  11. Buchwald, Dedra; Cheney, Paul R.; Peterson, Daniel L.; Henry, Berch; Wormsley, Susan B.; Geiger, Ann; Ablashi, Dharam V.; Salahuddin, S. Zaki; Saxinger, Carl; Biddle, Royce; Kikinis, Ron; Jolesz, Ferenc A.; Folks, Thomas; Balachandran, N.; Peter, James B.; Gallo, Robert C.; Komaroff, Anthony L. (1992), "A chronic illness characterized by fatigue, neurologic and immunologic disorders, and active human herpesvirus type 6 infection", Annals of Internal Medicine, 116 (2): 103-113, PMID 1309285
  12. Levine, Paul H.; Jacobson, Steven; Pocinki, Alan G.; Cheney, Paul; Peterson, Daniel; Connelly, Roger R; Weil, R; Robinson, SM; Ablashi, Dharam V; Salahuddin, Sayeef Z; Pearson, GR; Hoover, R (1992), "Clinical, Epidemiologic, and Virologic Studies in Four Clusters of the Chronic Fatigue Syndrome", Archives of Internal Medicine, 152 (8): 1611-1616, doi:10.1001/archinte.1992.00400200049009
  13. Strayer, DR; Carter, W; Strauss, KI; Brodsky, I; Suhadolnik, R; Ablashi, D; Henry, B; Mitchell, WM; Bastien, S; Peterson, D (1995), "Long Term Improvements in Patients with Chronic Fatigue Syndrome Treated with Ampligen", Journal of Chronic Fatigue Syndrome, 1 (1): 35-53, doi:10.1300/J092v01n01_04
  14. Peterson, Daniel L. (January 1997). "Chronic Fatigue Syndrome and Disability". Journal of Chronic Fatigue Syndrome. 3 (4): 5–7. doi:10.1300/j092v03n04_02. ISSN 1057-3321.
  15. Levine, Paul H.; Pilkington, Deborah; Strickland, Paula; Peterson, Daniel (2000), "Chronic Fatigue Syndrome and Cancer", Journal of Chronic Fatigue Syndrome, 7 (1): 29-38, doi:10.1300/J092v07n01_04
  16. Strickland, Paula S.; Levine, Paul H.; Peterson, Daniel L.; O'Brien, Karen; Fears, Thomas (January 2001). "Neuromyasthenia and Chronic Fatigue Syndrome (CFS) in Northern Nevada/California". Journal of Chronic Fatigue Syndrome. 9 (3–4): 3–14. doi:10.1300/j092v09n03_02. ISSN 1057-3321.
  17. Carruthers, Bruce M.; Jain, Anil Kumar; De Meirleir, Kenny L.; Peterson, Daniel L.; Klimas, Nancy G.; Lerner, A. Martin; Bested, Alison C.; Flor-Henry, Pierre; Joshi, Pradip; Powles, AC Peter; Sherkey, Jeffrey; van de Sande, Marjorie (January 2003). "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome". Journal of Chronic Fatigue Syndrome. 11 (1): 7–115. doi:10.1300/j092v11n01_02. ISSN 1057-3321.
  18. Suhadolnik, Robert J.; Peterson, Daniel L.; Reichenbach, Nancy L.; Roen, Gail; Metzger, Melodie; McCahan, John; O'Brien, Karen; Welsch, Suzanne; Gabriel, Jerome; Gaughan, John P.; McGregor, Neil R. (2004). "Clinical and Biochemical Characteristics Differentiating Chronic Fatigue Syndrome from Major Depression and Healthy Control Populations: Relation to Dysfunction in the RNase L Pathway". Journal of Chronic Fatigue Syndrome. 12 (1): 5–35. doi:10.1300/J092v12n01_02.
  19. Alter, Harvey J.; Mikovits, Judy A.; Switzer, William M.; Ruscetti, Francis W.; Lo, Shyh-Ching; Klimas, Nancy; Komaroff, Anthony L.; Montoya, Jose G.; Bateman, Lucinda; Levine, Susan; Peterson, Daniel; Levin, Bruce; Hanson, Maureen R.; Genfi, Afia; Bhat, Meera; Zheng, HaoQiang; Wang, Richard; Li, Bingjie; Hung, Guo-Chiuan; Lee, Li Ling; Sameroff, Stephen; Heneine, Walid; Coffin, John; Hornig, Mady; Lipkin, W. Ian (2012), "A Multicenter Blinded Analysis Indicates No Association between Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and either Xenotropic Murine Leukemia Virus-Related Virus or Polytropic Murine Leukemia Virus", mBio, 3 (5): e00266–12, doi:10.1128/mBio.00266-12
  20. Strayer, DR; Carter, WA; Stouch, BC; Stevens, SR; Bateman, L; Cimoch, PJ; Lapp, CW; Peterson, DL; Chronic Fatigue Syndrome AMP-516 Study Group; Mitchell, WM (2012), "A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome.", PLoS One, 7 (3): e31334, doi:10.1371/journal.pone.0031334, PMID 22431963
  21. Irlbeck, David M.; Vernon, Suzanne D.; McCleary, K. Kimberly; Bateman, Lucinda; Klimas, Nancy G.; Lapp, Charles W.; Peterson, Daniel L.; Brown, James R.; Remlinger, Katja S.; Wilfret, David A.; Gerondelis, Peter (2014). "No association found between the detection of either xenotropic murine leukemia virus-related virus or polytropic murine leukemia virus and chronic fatigue syndrome in a blinded, multi-site, prospective study by the establishment and use of the SolveCFS BioBank". BMC Research Notes. 7: 461. doi:10.1186/1756-0500-7-461.
  22. Peterson, D; Brenu, EW; Gottschalk, G; Ramos, SB; Nguyen, T; Staines, D; Marshall-Gradisnik, S (2015), "Cytokines in the Cerebrospinal Fluids of Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis", Mediators of Inflammation, 2015, doi:10.1155/2015/929720
  23. Klimas, N.G.; Ironson, G.; Carter, A.; Balbin, E.; Bateman, L.; Felsenstein, D.; Levine, S.; Peterson, D.; Chiu, K.; Allen, A.; Cunningham, K.; Gottschalk, C.G.; Fletcher, M; Hornig, M.; Canning, C.; Komaroff, A.L. (2015), "Findings from a clinical and laboratory database developed for discovery of pathogenic mechanisms in myalgic encephalomyelitis/chronic fatigue syndrome", Fatigue: Biomedicine, Health & Behavior, 3 (2): 75-96, doi:10.1080/21641846.2015.1023652
  24. Bateman, L.; Darakjy, S.; Klimas, N.; Peterson, D.; Levine, S.M.; Allen, A.; Carlson, S.A.; Balbin, E.G.; Gottschalk, G.; March, D. (2015), "Chronic fatigue syndrome and co-morbid and consequent conditions: evidence from a multi-site clinical epidemiology study", Fatigue: Biomedicine, Health & Behavior, 3 (1): 1-15, doi:10.1080/21641846.2014.978109
  25. Hornig, M; Montoya, JG; Klimas, NG; Levine, SM; Felsenstein, D; Bateman, L; Peterson, DL; Gottschalk, CG; Schultz, AF; Che, X; Eddy, ML; Komaroff, AL; Lipkin, WI (2015). "Distinct plasma immune signatures in ME/CFS are present early in the course of illness". Science Advances. 1 (1). doi:10.1126/sciadv.1400121.
  26. Hornig, M; Gottschalk, G; Peterson, D; Knox, KK; Schultz, AF; Eddy, ML; Che, X; Lipkin, WI (2016), "Cytokine network analysis of cerebrospinal fluid in myalgic encephalomyelitis/chronic fatigue syndrome.", Molecular Psychiatry, 21 (2): 261-9, doi:10.1038/mp.2015.29
  27. Nagy-Szakal, Dorottya; Williams, Brent L.; Mishra, Nischay; Che, Xiaoyu; Lee, Bohyun; Bateman, Lucinda; Klimas, Nancy G.; Komaroff, Anthony L.; Levine, Susan; Montoya, Jose G.; Peterson, Daniel L.; Ramanan, Devi; Jain, Komal; Eddy, Meredith L.; Hornig, Mady; Lipkin, W. Ian (2017), "Fecal metagenomic profiles in subgroups of patients with myalgic encephalomyelitis/chronic fatigue syndrome", Microbiome, 5 (44), doi:10.1186/s40168-017-0261-y
  28. Unger, Elizabeth R.; Lin, Jin-Mann S.; Tian, Hao; Natelson, Benjamin H; Lange, Gudrun; Vu, Diana; Blate, Michelle; Klimas, Nancy G.; Balbin, Elizabeth G.; Bateman, Lucinda; Allen, Ali; Lapp, Charles W.; Springs, Wendy; Kogelnik, Andreas M.; Phan, Catrina C.; Danver, Joan; Podell, Richard N.; Fitzpatrick, Trisha; Peterson, Daniel L.; Gottschalk, C. Gunnar; Rajeevan, Mangalathu S.; MCAM Study Group (2017), "Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study.", American Journal of Epidemiology, 1–10, doi:10.1093/aje/kwx029
  29. Hornig, M; Gottschalk, G; Eddy, ML; Che, X; Ukaigwe, JE; Peterson, DL; Lipkin, WI (2017), "Immune network analysis of cerebrospinal fluid in myalgic encephalomyelitis/chronic fatigue syndrome with atypical and classical presentations", Translational Psychiatry, 7 (4), doi:10.1038/tp.2017.44
  30. Marshall-Gradisnik, Sonya; Fretel, Marshall; Eaton, Natalie; Cabanas, Helene; Balinas, Cassandra; Gopalan, Vinod; Petersen, Daniel; Passmore, Rachel; Tang, Kevin; Haque, Mazhar; Lam, Alfred; Staines, Donald (May 31, 2018). "Decreased Expression of TRPM3 and mAChRM3 in the Small Intestine in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis". International Journal of Clinical Medicine. 09 (05): 467. doi:10.4236/ijcm.2018.95040.
  31. Nagy-Szakal, Dorottya; Barupal, Dinesh K.; Lee, Bohyun; Che, Xiaoyu; Williams, Brent L.; Kahn, Ellie J.R.; Ukaigwe, Joy E.; Bateman, Lucinda; Klimas, Nancy G.; Komaroff, Anthony L.; Levine, Susan; Montoya, Jose G.; Peterson, Daniel L.; Levin, Bruce; Hornig, Mady; Fiehn, Oliver; Lipkin, W. Ian (2018), "Insights into myalgic encephalomyelitis/chronic fatigue syndrome phenotypes through comprehensive metabolomics", Scientific Reports, 8 (1): 10056, doi:10.1038/s41598-018-28477-9
  32. Mandarano, Alexandra H.; Maya, Jessica; Giloteaux, Ludovic; Peterson, Daniel L.; Maynard, Marco; Gottschalk, C. Gunnar; Hanson, Maureen R.; Maureen Hanson (February 10, 2020). "Myalgic encephalomyelitis/chronic fatigue syndrome patients exhibit altered T cell metabolism and cytokine associations". Journal of Clinical Investigation. 130 (3): 1491–1505. doi:10.1172/jci132185.
  33. Avik, R; Gottschalk, Carl G; Peterson, Daniel; Knox, K; Maynard, M; Whelan, RJ (September 29, 2021). "Molecular evidence of autophagy impairment as serum level of ATG13 is elevated in patients with myalgic encephalomyelitis and chronic fatigue syndrome: two independent case-control studies". Researchsquare. doi:10.21203/rs.3.rs-925403/v1. Retrieved November 5, 2022.
  34. Gottschalk, Carl G; Peterson, Daniel; Knox, Konstance; Maynard, Marco; Whelan, Ryan J.; Roy, Avik (May 1, 2022). "Elevated ATG13 in serum of patients with ME/CFS stimulates oxidative stress response in microglial cells via activation of receptor for advanced glycation end products (RAGE)". Molecular and Cellular Neuroscience. 120: 103731. doi:10.1016/j.mcn.2022.103731. ISSN 1044-7431.
  35. "IIMEC4". Invest in ME Research. Retrieved February 4, 2020.
  36. "IIMEC7 International ME Conference 2012". Invest in ME Research. Retrieved February 4, 2020.
  37. "IIMEC8 International ME Conference 2013". Invest in ME Research. Retrieved February 4, 2020.
  38. CFS and the CDC's Failure to Respond: Primetime Live (1996), retrieved February 4, 2020
  39. I Remember Me, retrieved February 4, 2020

immunomodulator An immunomodulator is a substance that affects the functioning of the immune system

myalgic encephalomyelitis (M.E.) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

double blinded trial A clinical trial is double blinded if neither the participants nor the researchers know which treatment group they are allocated to until after the results are interpreted. This reduces bias. (Learn more: www.nottingham.ac.uk)

agonist A chemical that binds to the receptor and stimulates it's function, e.g., morphine is an opioid agonist that binds to the opioid receptor, reducing pain. The opposite of an antagonist.

blinded trial A clinical trial is blinded if either the participants or the researchers don't know which treatment group they are allocated to until after the results are interpreted. (Learn more: www.nottingham.ac.uk)

myalgic encephalomyelitis (M.E.) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

serum The clear yellowish fluid that remains from blood plasma after clotting factors have been removed by clot formation. (Blood plasma is simply blood that has had its blood cells removed.)

microglia A type of immune cell, called a macrophage, that lives in the brain. For historical reasons, macrophages have different names based on the part of the body that they normally live in. Macrophages that normally live in the blood are called monocytes. Macrophages that normally live in the skin are called Langerhans cells. Macrophages that normally live in the liver are called Kupffer cells. And macrophages that normally live in the central nervous system are called microglia. Microglia were originally classified as glial cells, under the assumption that the cells had a merely structural function, before it was realized that the cells were in fact immune cells. As the "sentinel cells" of the central nervous system, microglia survey their environment for abnormalities such as infection or tissue damage, and then initiate an immune response to fight the infection or repair the tissue damage.

cytokine any class of immunoregulatory proteins secreted by cells, especially immune cells. Cytokines are small proteins important in cell signaling that modulate the immune system. (Learn more: me-pedia.org)

microbiome The full collection of microscopic organisms (especially bacteria and fungi) which are present in a particular environment, particularly inside the human body.

The information provided at this site is not intended to diagnose or treat any illness.
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history.